Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4944.46
ONVO's Cash to Debt is ranked higher than
86% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. ONVO: 4944.46 )
ONVO' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: 4944.46

Equity to Asset 0.95
ONVO's Equity to Asset is ranked higher than
97% of the 244 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. ONVO: 0.95 )
ONVO' s 10-Year Equity to Asset Range
Min: -7.39   Max: 0.96
Current: 0.95

-7.39
0.96
F-Score: 3
Z-Score: 86.80
M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -6686.22
ONVO's Operating margin (%) is ranked lower than
52% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.36 vs. ONVO: -6686.22 )
ONVO' s 10-Year Operating margin (%) Range
Min: -5448.28   Max: -778.53
Current: -6686.22

-5448.28
-778.53
Net-margin (%) -6762.16
ONVO's Net-margin (%) is ranked lower than
53% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. ONVO: -6762.16 )
ONVO' s 10-Year Net-margin (%) Range
Min: -6820.05   Max: -3638.51
Current: -6762.16

-6820.05
-3638.51
ROE (%) -54.80
ONVO's ROE (%) is ranked higher than
54% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ONVO: -54.80 )
ONVO' s 10-Year ROE (%) Range
Min: -120.28   Max: -120.28
Current: -54.8

ROA (%) -51.86
ONVO's ROA (%) is ranked higher than
56% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.94 vs. ONVO: -51.86 )
ONVO' s 10-Year ROA (%) Range
Min: -519.94   Max: -77.23
Current: -51.86

-519.94
-77.23
ROC (Joel Greenblatt) (%) -2627.34
ONVO's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. ONVO: -2627.34 )
ONVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2628.77   Max: -2610.36
Current: -2627.34

-2628.77
-2610.36
» ONVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ONVO Guru Trades in Q1 2014

Paul Tudor Jones 17,792 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

ONVO Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

ONVO Guru Trades in Q3 2014

Paul Tudor Jones 30,491 sh (New)
» More
Q4 2014

ONVO Guru Trades in Q4 2014

Chase Coleman 500,000 sh (New)
Paul Tudor Jones 11,961 sh (-60.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.40
ONVO's P/B is ranked higher than
59% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. ONVO: 8.40 )
ONVO' s 10-Year P/B Range
Min: 7.59   Max: 61.09
Current: 8.4

7.59
61.09
P/S 1076.40
ONVO's P/S is ranked higher than
53% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.52 vs. ONVO: 1076.40 )
ONVO' s 10-Year P/S Range
Min: 71   Max: 1250
Current: 1076.4

71
1250
EV-to-EBIT -16.81
ONVO's EV-to-EBIT is ranked higher than
58% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ONVO: -16.81 )
ONVO' s 10-Year EV-to-EBIT Range
Min: -138.4   Max: -10.9
Current: -16.81

-138.4
-10.9
Current Ratio 17.71
ONVO's Current Ratio is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. ONVO: 17.71 )
ONVO' s 10-Year Current Ratio Range
Min: 0.04   Max: 34
Current: 17.71

0.04
34
Quick Ratio 17.68
ONVO's Quick Ratio is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. ONVO: 17.68 )
ONVO' s 10-Year Quick Ratio Range
Min: 0.04   Max: 34
Current: 17.68

0.04
34
Days Sales Outstanding 27.44
ONVO's Days Sales Outstanding is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 81.46 vs. ONVO: 27.44 )
ONVO' s 10-Year Days Sales Outstanding Range
Min: 49.4   Max: 49.4
Current: 27.44

Valuation & Return

vs
industry
vs
history
Price/Net Cash 8.90
ONVO's Price/Net Cash is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ONVO: 8.90 )
ONVO' s 10-Year Price/Net Cash Range
Min: 8.74   Max: 47.25
Current: 8.9

8.74
47.25
Price/Net Current Asset Value 8.90
ONVO's Price/Net Current Asset Value is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. ONVO: 8.90 )
ONVO' s 10-Year Price/Net Current Asset Value Range
Min: 8.74   Max: 47.25
Current: 8.9

8.74
47.25
Price/Tangible Book 8.70
ONVO's Price/Tangible Book is ranked higher than
69% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.30 vs. ONVO: 8.70 )
ONVO' s 10-Year Price/Tangible Book Range
Min: 8.49   Max: 34.36
Current: 8.7

8.49
34.36
Earnings Yield (Greenblatt) -6.20
ONVO's Earnings Yield (Greenblatt) is ranked higher than
62% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. ONVO: -6.20 )
ONVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.8   Max: 0
Current: -6.2

-6.8
0

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:4OR.Germany, 0R02.UK, ONVO.Switzerland,
Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.
» More Articles for ONVO

Headlines

Articles On GuruFocus.com
2015 Must-Buys In Biotech Sector Feb 02 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 
This 3D Printing Company Is a Solid Long-Term Buy Jul 26 2014 
Why Organovo Is a Better Buy Than 3D Systems May 14 2014 
Dump 3D Systems and Buy Organovo May 09 2014 
Why Organovo Is The Only 3D Printing Company Worth Buying Apr 25 2014 

More From Other Websites
5 Live Investor Webcasts from Aflac and Life Sciences Companies: March 5 at... Mar 03 2015
5 Live Investor Webcasts from Aflac and Life Sciences Companies: March 5 at... Mar 03 2015
Will 3D Printing Be A Part Of The Future? Feb 27 2015
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive... Feb 27 2015
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive... Feb 27 2015
Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive... Feb 27 2015
Why Should Investors Be Wary Of Organovo? Feb 23 2015
ORGANOVO HOLDINGS, INC. Financials Feb 13 2015
Bioprinting Profits: Why Organovo’s 3-D Bioprinting Technology Isn’t Worth Investment Feb 09 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 09 2015
Organovo Holdings, Inc. Reports Third Quarter Results Feb 09 2015
Organovo Holdings, Inc. Reports Third Quarter Results Feb 09 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Regulation FD Disclosure Feb 06 2015
ORGANOVO HOLDINGS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 30 2014
Exclusive: Organovo CEO On The Role Of 3D Printing In Health Care Dec 23 2014
Cramer: It's the right time to buy this stock Dec 16 2014
Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product Dec 15 2014
Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product Dec 15 2014
Organovo Holdings CEO Won't Rule Out Sale Dec 13 2014
Stock Pops & Drops: COST, IBM, AAPL & ONVO Dec 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK